Juli Owczarek

Juli Owczarek currently serves as an Executive Oncology Account Manager at Exelixis, where responsibilities include the launch of Cabometyx in the renal cell carcinoma sector and expanding its market presence with subsequent approvals for liver and thyroid cancers. Prior experience includes roles as a Senior Oncology Specialist at Gilead Sciences, where Juli launched Zydelig in the lymphoma and leukemia markets, and as a Senior Oncology Specialist at Onyx Pharmaceuticals, where Juli launched Kyprolis for multiple myeloma. Juli gained experience at Bristol-Myers Squibb first as an Executive Oncology Specialist, contributing to the growth of Erbitux and Sprycel markets, and earlier as a Neuroscience Institutional Specialist and Territory Manager. Juli holds a Master of Science in Administration with a focus on International Marketing from Central Michigan University and a Bachelor of Science in Medical Laboratory Sciences from Oakland University.